1448 related articles for article (PubMed ID: 22331582)
21. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.
Finazzi G; Barbui T
Leukemia; 2008 Aug; 22(8):1494-502. PubMed ID: 18596737
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic options for essential thrombocythemia and polycythemia vera.
Solberg LA
Semin Oncol; 2002 Jun; 29(3 Suppl 10):10-5. PubMed ID: 12096352
[TBL] [Abstract][Full Text] [Related]
23. New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera.
Tefferi A; Barbui T
Am J Hematol; 2015 Aug; 90(8):683-5. PubMed ID: 25872987
[No Abstract] [Full Text] [Related]
24. Contemporary approach to essential thrombocythemia and polycythemia vera.
Aruch D; Mascarenhas J
Curr Opin Hematol; 2016 Mar; 23(2):150-60. PubMed ID: 26717193
[TBL] [Abstract][Full Text] [Related]
25. Expertise-based management in essential thrombocythemia and polycythemia vera.
Finazzi G; Barbui T
Cancer J; 2007; 13(6):372-6. PubMed ID: 18032974
[TBL] [Abstract][Full Text] [Related]
26. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia.
Elliott MA; Tefferi A
Semin Thromb Hemost; 1997; 23(5):463-72. PubMed ID: 9387205
[TBL] [Abstract][Full Text] [Related]
27. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
[TBL] [Abstract][Full Text] [Related]
28. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
Barbui T; Finazzi G
Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
[TBL] [Abstract][Full Text] [Related]
29. How to manage polycythemia vera.
Passamonti F
Leukemia; 2012 May; 26(5):870-4. PubMed ID: 22157736
[TBL] [Abstract][Full Text] [Related]
30. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
31. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
32. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
Murphy S
Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227
[TBL] [Abstract][Full Text] [Related]
34. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.
Cerquozzi S; Tefferi A
Blood Cancer J; 2015 Nov; 5(11):e366. PubMed ID: 26565403
[TBL] [Abstract][Full Text] [Related]
35. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
36. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
Finazzi G; Barbui T
Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
[TBL] [Abstract][Full Text] [Related]
37. It is time to change thrombosis risk assessment for PV and ET?
Passamonti F; Caramazza D; Mora B; Casalone R; Maffioli M
Best Pract Res Clin Haematol; 2014 Jun; 27(2):121-7. PubMed ID: 25189723
[TBL] [Abstract][Full Text] [Related]
38. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
39. Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera.
Elliott MA; Tefferi A
Curr Hematol Rep; 2004 Sep; 3(5):344-51. PubMed ID: 15341701
[TBL] [Abstract][Full Text] [Related]
40. [Treatment of myeloproliferative neoplasms other than chronic leukemia].
Ohyashiki JH
Nihon Rinsho; 2009 Oct; 67(10):1964-8. PubMed ID: 19860198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
